<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="260">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816084</url>
  </required_header>
  <id_info>
    <org_study_id>2020-004-SERUR</org_study_id>
    <nct_id>NCT04816084</nct_id>
  </id_info>
  <brief_title>SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes</brief_title>
  <acronym>SERUR</acronym>
  <official_title>SERUR : Etude sérologique COVID-19 (Anti-SARS CoV 2) du Personnel de l'Université de Reims Champagne-Ardenne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Reims Champagne-Ardenne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Reims Champagne-Ardenne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to determine, in a screening situation within the framework of&#xD;
      university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the&#xD;
      staff of the University of Reims Champagne-Ardenne. The serological tests chosen will allow&#xD;
      systematic detection of anti-SARS-CoV-2 IgM and anti-SARS-Cov-2 IgG to assess the moment of&#xD;
      potential contamination prior to resumption of occupational activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      This study was designed to determine, in a screening situation within the framework of&#xD;
      university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the&#xD;
      staff of the University of Reims Champagne-Ardenne. The serological tests chosen will allow&#xD;
      systematic detection of anti-SARS-CoV-2 IgM and anti-SARS-Cov-2 IgG to assess the moment of&#xD;
      potential contamination prior to resumption of occupational activity.&#xD;
&#xD;
      Type of study:&#xD;
&#xD;
      This is a prevalence study, a single-center cross-sectional study published on the human&#xD;
      person.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      Inclusion criteria: On a voluntary basis, the staff of the University of Reims Champagne&#xD;
      Ardenne will be offered a serological blood test (1 dry tube of 7ml). The use of the&#xD;
      collected data for research purposes will be explained to each requester, with signature of&#xD;
      an informed consent. Only people over 18 will be included.&#xD;
&#xD;
      Non-inclusion criteria: Staff of the University of Reims Champagne Ardenne who have not&#xD;
      requested to be tested. Duration of participation of subjects: 1/2 day time&#xD;
&#xD;
      Judgment criterion (s):&#xD;
&#xD;
      Main endpoint (in connection with the main objective): Prevalence of positive SARS-CoV-2&#xD;
      serology at the University of Reims Champagne-Ardenne.&#xD;
&#xD;
      Clinical investigation plan:&#xD;
&#xD;
        -  Phase 1: Communication strategy An email will be sent to all the staff of the University&#xD;
           of Reims Champagne Ardenne to offer them anti-SARS-Cov-2 serological tests, as part of a&#xD;
           health research protocol. Before sampling, a questionnaire will be completed by the&#xD;
           applicant.&#xD;
&#xD;
        -  Phase 2: Analysis of the samples&#xD;
&#xD;
        -  Phase 3: Transmission of results to Pr Frédéric Deschamps, head of SUMMPS at the&#xD;
           University of Reims Champagne Ardenne&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of IgG and IgM anti-SARS CoV2 antibodies</measure>
    <time_frame>Inclusion time was ½ day, time for blood sampling</time_frame>
    <description>Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">389</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Anti-SARS-CoV2 Serology</intervention_name>
    <description>Diagnostic Test: Anti-SARS-CoV2 Serology A blood sample is collected by venipuncture at Day 0. The anti-SARS-CoV2 serological status is measured by with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays (EUROBIO®)&#xD;
Other: Questionnaire&#xD;
Data concerning personal exposure factors are collected in a questionnaire:&#xD;
Socio-demographic factors: sex, age,&#xD;
known risk-factor for Covid-19&#xD;
Professional factors: Employment (type, work time, location), protective measures put in place to reduce the risk of contamination&#xD;
Non-professional factors: Contact with infected individuals, carrying of protective equipment and compliance with barrier measures, transport and accomodation modalities during holidays</description>
    <arm_group_label>Population</arm_group_label>
    <other_name>other : questionnaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major volunteers from the Staff of the University of Reims Champagne-Ardenne (&gt;18&#xD;
             years old)&#xD;
&#xD;
        Exclusion Criteria (Non Inclusion):&#xD;
&#xD;
          -  persons who do not desire to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine GIUSTI, MCU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Reims CHampahne-Ardenne - CHU de Reims</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université de Reims Champagne-Ardenne</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV2 antibodies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

